Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02058290 · ClinicalTrials.gov registry record · Phase 4
A Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy
A Phase 4 study, sponsored by Pacira Pharmaceuticals.
- Terminated
- Registry status
- Phase 4
- Development phase
- 122
- Enrollment target
NCT02058290 is a Phase 4 study that was terminated before completion, run by Pacira Pharmaceuticals. The registered enrollment target is 122 participants.
The verdict
NCT02058290, a Phase 4 study, was terminated before completion, sponsored by Pacira Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 122 participants
- Enrollment target
Study Summary
This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospital costs.
Interventions
- DRUG EXPAREL
- DRUG IV morphine sulfate or Sponsor-approved equivalent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02058290
The ClinicalTrials.gov registry entry for NCT02058290 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EXPAREL is the first listed.
NCT02058290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02058290 about?
NCT02058290 is a clinical study titled "A Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy". This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospital costs.
What is the current status of trial NCT02058290?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 122 participants. The study started on 2011-12. Estimated completion is 2013-02.
What interventions are being tested in trial NCT02058290?
The interventions under investigation include: EXPAREL (DRUG), IV morphine sulfate or Sponsor-approved equivalent (DRUG).
Who is sponsoring clinical trial NCT02058290?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.